• DOI:10.1111/j.1365-2222.2004.1965.x
Corpus ID: 1480600

Topical treatment with aqueous solutions of rofleponide palmitate and budesonide in a pollen‐season model of allergic rhinitis

@article{AhlstrmEmanuelsson2004TopicalTW,
  title={Topical treatment with aqueous solutions of rofleponide palmitate and budesonide in a pollen‐season model of allergic rhinitis},
  author={C. Ahlstr{\"o}m-Emanuelsson and M. Andersson and C. Persson and C. Schrewelius and L. Greiff},
  journal={Clinical & Experimental Allergy},
  year={2004},
  volume={34}
}

C. Ahlström-Emanuelsson, M. Andersson, +2 authors L. Greiff

Published 2004

Medicine

Clinical & Experimental Allergy

View on Wiley

ncbi.nlm.nih.gov

Save to Library

Create Alert

Cite

Launch Research Feed

Background Rofleponide palmitate is an esterified glucocorticosteroid pro‐drug with a promising pre‐clinical profile designed to deliver topical airway treatment for allergic rhinitis and asthma in a novel manner. Thus, the rofleponide palmitate pro‐drug is designed to provide topical exposure of the mucosa to the inactive lipophilic drug, which would be locally metabolized to the more hydrophilic and readily cleared drug rofleponide.